The female reproductive system has been extensively analyzed for the presence of steroid receptor proteins, both in normal and malignant states [1] [2] [3] [4] [5] [6] [7] [8] . In breast cancer, estrogen and progestin receptor content has been established as an important predictor of response to therapy and a predictor of survival [9] [10] [11] [12] [13] [14] [15] . In the United States, endometrial cancer is the most common gynecologic malignancy and it has been most frequently studied for the existence of steroid receptor proteins [16] . Many clinicopathologic features of this disease have been shown to be associated with prognosis, including stage of the disease, histologic grade of the tumor, histologic subtype, age of the patient, nuclear grade of the tumor, depth of myometrial invasion by the tumor, pelvic and/or periaortic nodal status, and status of the peritoneal washings [17] [18] [19] [20] [21] [22] . More recently, sex steroid receptor proteins in the tumor have been studied, and the receptor levels have been correlated with many of these predictive parameters [6, 17, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Furthermore, the hormone receptor status of the tumor has been correlated with absolute and disease-free survival [23] [24] [25] [26] [27] [28] [29] [30] 37] and with response of recurrent and advanced disease to hormonal therapy and/or cytotoxic chemotherapy [6, 29, 34, [38] [39] [40] . This review of the English-language literature from 1980 will outline these investigations and analyze especially the predictive value of the level of the sex steroid receptor in the tumor as a prognosticator for survival.
INTRODUCTION
The female reproductive system has been extensively analyzed for the presence of steroid receptor proteins, both in normal and malignant states [1] [2] [3] [4] [5] [6] [7] [8] . In breast cancer, estrogen and progestin receptor content has been established as an important predictor of response to therapy and a predictor of survival [9] [10] [11] [12] [13] [14] [15] . In the United States, endometrial cancer is the most common gynecologic malignancy and it has been most frequently studied for the existence of steroid receptor proteins [16] . Many clinicopathologic features of this disease have been shown to be associated with prognosis, including stage of the disease, histologic grade of the tumor, histologic subtype, age of the patient, nuclear grade of the tumor, depth of myometrial invasion by the tumor, pelvic and/or periaortic nodal status, and status of the peritoneal washings [17] [18] [19] [20] [21] [22] . More recently, sex steroid receptor proteins in the tumor have been studied, and the receptor levels have been correlated with many of these predictive parameters [6, 17, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Furthermore, the hormone receptor status of the tumor has been correlated with absolute and disease-free survival [23] [24] [25] [26] [27] [28] [29] [30] 37] and with response of recurrent and advanced disease to hormonal therapy and/or cytotoxic chemotherapy [6, 29, 34, [38] [39] [40] . This review of the English-language literature from 1980 will outline these investigations and analyze especially the predictive value of the level of the sex steroid receptor in the tumor as a prognosticator for survival.
SEX STEROID RECEPTOR PROTEIN ANALYSIS The usual technique in the clinical literature for assaying the steroid receptor protein in tumors involves a cytosol analysis for the unoccupied receptor. Briefly, the tissue obtained either from a uterine curettage or directly from the endometrium after hysterectomy is dissected into a tumor component and a connective and adipose tissue component. The tumor specimen is stored at -700C until analysis. The specimen is then homogenized and centrifuged to produce a soluble cytoplasmic fraction. The protein in the cytoplasmic fraction and/or the DNA in the particulate fraction are 339 quantitated. The total bound steroid ligand levels are obtained by incubating an aliquot of the cytosol with the appropriate radiolabeled steroid at various temperature and time considerations in order to reach binding equilibrium. Nonspecific bound steroid levels are obtained by simultaneously incubating in the presence of 100-fold molar excess of non-radiolabeled competitor. With such a large concentration of competitor, the radiolabeled steroid is displaced from the receptor binding sites that are present in a limited number but not from the high-capacity, nonspecific binding sites. The receptor binding capacity is calculated by subtracting the level of cytosol nonspecific bound steroid ligand from the total cytosol bound radioligand. The separation of the free and receptor-bound radioligand is then usually done by one of the following methods: sucrose density gradient sedimentation, selective adsorption of unbound steroid on dextran-coated charcoal, adsorption of the receptor-steroid complex (e.g., to hydroxylapatite), or gel filtration. The radioactivity associated with specific binding and the specific activity of the radiolabeled steroid are used to determine the steroid receptor levels. The levels of steroid receptor protein are expressed in femtomoles (10-" moles) of radiolabeled steroid bound per milligram of cytosol protein or per milligram of DNA [41 ] . Because of the various biochemical methods used, the levels of receptor protein reported will differ. Some methods measure the total binding or sites by "exchange" assays, as opposed to measurement of only unoccupied receptor sites. Other factors which may affect the level obtained include: single-point determination of protein binding versus a Scatchard analysis, determination of cytosol fractions versus total fraction, or inclusion or non-inclusion of reagents in the assay to prevent the binding of radioactive ligand to serum binding proteins [42] .
In the older literature, the receptor was postulated to be in the cytosol component, and assays were therefore reported as cytoplasmic steroid receptor analyses. The current theory regarding the estrogen receptor protein postulates that the unoccupied estrogen receptor is a nuclear protein bound by low-affinity interactions to nuclear components. Estrogen, a lipophilic compound, diffuses through the cellular membrane, the cytoplasm, and the nuclear envelope, where it reacts with the nuclear receptor in target cells. Next a conformational change in the receptor complex leads to new physical properties and a high affinity for nuclear components, including chromatin proteins, the nuclear matrix, and DNA. This change causes an increase in transcription of a variety of genes in these target cells. The progestin receptor is thought to be synthesized in response to the successful interaction of estrogen with its own receptor protein [43] .
Early Observations on Hormonal Therapy
The treatment of endometrial cancer with hormones, in particular with progestins, was established prior to the biochemical identification of estrogen and progestin receptors [44] . Several initial reports recognized that many factors influenced the sensitivity of the endometrial cancer to hormonal manipulation, including the extent and location of metastatic disease, location of metastases outside the radiation ports, histologic differentiation, time interval between the initial treatment and recurrence, the age of the patient at diagnosis, therapeutic modalities prior to hormonal therapy, the type of progestin therapy used, and the length of treatment [33] . It was only later, with the identification of the receptor proteins, that a rational basis for these observations could be developed.
Sampling Problems
Most clinical studies on the receptor content in endometrial cancer are based on tissue obtained from curettings at the time of dilatation and curettage. This method leads to contamination with non-malignant fragments, including glandular and stromal components. Even in the postmenopausal uterus, the normal endometrium may have elevated steroid receptor levels. Mortel et al. [31] , clearly outlined cell heterogeneity, tissue heterogeneity, and tumor heterogeneity as the problems which interfered with receptor determinations when using this technique of obtaining tissue. Cell heterogeneity refers to the fact that the endometrium is composed of two major cell types: glandular epithelium and stroma. Since endometrial cancer arises from the epithelial cells, the determination of steroid receptor levels should reflect the levels in these cells and not in those of the stromal component, which may also contain the receptor proteins. Hence, techniques for separating the glandular elements from the stroma may be necessary in order to determine the steroid levels more accurately, since Mortel et al. [31] have shown an increased level of progestin receptor in the isolated glandular element free of stroma compared to the undissociated tissue. Tissue heterogeneity refers to the fact that the curetting may contain not only cancerous glandular elements, but also normal or hyperplastic endometria. These benign components of glandular tissue may have high levels of steroid receptors, and so even a small fragment will alter the value obtained from the analysis of the tissue homogenate. Finally, tumor heterogeneity refers to the fact that it is not uncommon for a tumor to be composed of various degrees of dedifferentiation of the glandular element. Hence, the biochemical determination on a fragment of cancer will depend on the degree of differentiation in the sample, which may not reflect the tumor as a whole. As will be noted later, the level of tumor differentiation correlates with the level of the steroid receptor obtained. Tsibris et al. have shown that the steroid receptor proteins have an uneven distribution throughout the endometrial cavity [45] . Soper et al. [46] , in a review of 422 specimens submitted for biochemical analysis of steroid receptor levels, found that 4.0 percent of the specimens had no evidence of carcinoma on permanent histologic section. Moreover, an additional 2.5 percent of the specimens contained only focal adenocarcinoma on permanent histologic sections but had no malignancy in the frozen section submitted for steroid receptor analysis. These specimens were obtained by endometrial biopsy or curettage, by hysterectomy, or by directed biopsy of metastatic lesions. In a subsequent review by the same authors [47] of 100 specimens submitted for analysis, histologic components other than malignant epithelium accounted for the majority of specimens in 20 percent of the cases, while in only 5 percent of the cases did the specimen contain only malignant cells. This finding emphasizes that contamination by non-malignant fragments causes inaccuracy in evaluating endometrial tumors by the biochemical method because it uses tissue homogenates. Additional technical problems arise with the biochemical analysis because a prolonged period between obtaining the tissue and processing the tissue may lead to loss of receptor protein.
IMMUNOHISTOCHEMICAL TECHNIQUES With the problem of contamination of the specimen by non-malignant components, the development of newer immunohistochemical techniques to localize the receptor to the malignant cells has become important. Only a limited number of clinical studies have appeared which address this problem in endometrial cancer. Initial studies using fluorescent-conjugated steroids or anti-steroid hormonal antibodies were unsuccessful [48, 49] . Mutch et al. [50] , in 96 specimens obtained at hysterectomy from patients with stages I to IV endometrial cancer, compared clinical and pathologic associations of biochemical and immunohistochemical estrogen receptor assays to evaluate the significance for the estrogen receptor contribution of the non-malignant components.
Using the monoclonal antibody H222 gamma, developed against the MCF-7 breast cancer estrogen receptor by Abbott Laboratories, and amplified by peroxidase/ antiperoxidase stains and a semi-quantitative scoring system incorporating both the intensity and distribution of the receptor, Mutch and co-workers demonstrated a 91.5 percent sensitivity and a 93.1 percent specificity for the immunohistochemical analysis compared with the biochemical analysis of estrogen receptor in the tissues. The cancer component semi-quantitative score derived from the immunohistochemical method correlated better with the histologic grade of the tumor than did the biochemical estrogen receptor determination. Decreasing biochemical estrogen receptor levels predicted advanced surgical stage (p = 0.0003), as did the total semi-quantitative coefficient (p = 0.0003) (sum of scores from four histologic components: benign epithelium, malignant epithelium, stroma, and myometrium). Although immunohistochemical analysis predicted biologic differentiation better than did the biochemical estrogen receptor analysis, stage correlated better with biochemical estrogen analysis and total semi-quantitative score than did the cancer component score. This study of endometrial cancer using immunohistochemical techniques for localization and quantification of the estrogen receptor to the malignant component may permit better understanding of the biologic behavior than techniques involving whole-tissue homogenates. Other studies in animal models for localization of the estrogen and progestin receptors have recently appeared in the literature [51] [52] [53] .
CLINICOPATHOLOGIC CORRELATIONS Many studies investigating the relationship between the steroid receptor level and histologic differentiation of the tumor have shown that the more differentiated the tumor, the higher the content of both estrogen and progestin receptor protein [6, [23] [24] [25] [26] [27] [28] [29] . Ehrlich et al. [6] reported the presence of cytoplasmic estrogen and progestin receptors in a spectrum of endometria ranging from normal to hyperplastic and cancerous states. A decreasing concentration of the progestin receptor activity was observed with increasing tumor dedifferentiation. Chambers et al. [23] , in an analysis of 213 postmenopausal women with primary endometrial cancer, showed that the mean estrogen receptor levels (p= 0.008) and mean progestin receptor levels (p = 0.0001) were related significantly in an inverse fashion to the histologic grade of the tumor and that the levels of the receptors (p = 0.0001) correlated with each other. Of 77 tumors from patients with stage I and II disease that were estrogen receptor-and progestin receptor-rich, 32.4 percent were well-differentiated adenocarcinomas and 15.5 percent were poorly differentiated adenocarcinomas, whereas, of 18 tumors in this group of patients that were estrogen receptor-and progestin receptor-poor, only 5.5 percent were well-differentiated tumors and 61.1 percent were poorly difflerentiated tumors. There are, however, reports that do not confirm the relationship between hormone receptor status and grade of the tumor [30, 32, 33] .
Receptor-rich tumors for endometrial cancer are defined arbitrarily with cut-off levels for positivity of the estrogen receptor ranging from 3 to greater than 100 fmol/mg of protein and for positivity of the progestin receptor ranging from 5 to greater than 100 fmol/mg of protein [6, [24] [25] [26] [27] [28] [29] [30] 37] . Thus comparing statements about the correlations of various clinicopathologic features and receptor status is difficult; furthermore, different biochemical assays are often employed, so that the level of the receptor content is also variable. Even with this problem, many statements concerning hormone receptor levels or status and outcome agree, as will be noted below.
Many authors have noted a correlation between the level or status of estrogen and progestin receptor and the stage of endometrial cancer [23, 24, 26, 27] . Chambers et al. [23] , in a review of 213 patients with stages I to IV endometrial cancer, showed that estrogen receptor positivity (>20 fmol/mg of protein) correlated with the stage of disease. On the other hand, progestin receptor positivity (>7 fmol/mg of protein) was not associated with stage of disease. Others have not observed this relatinship [30] .
The relationship between steroid receptor and histologic subtype has been investigated by many authors, but few have simultaneously controlled for the histologic differentiation of the tumor. For example, in Chambers et al. [23] , the mean estrogen receptor level for adenocarcinoma was 65.1 fmol/mg of protein compared with 29.0 fmol/mg of protein for the adenosquamous tumors; however, this latter group had predominantly poorly differentiated tumors. On the other hand, the progestin receptor levels did not significantly differ with histologic classification. Liao et al. [26] , in analyzing 86 cases of primary endometrial cancer, did not see a relationship between histologic subtype and hormonal receptor level of the tumor. Creasman et al. [25] , in a study of 168 patients with stages I and II endometrial cancer, found a statistically significant relationship between progestin receptor status and histologic subtypes; however, the grade of the tumors was not controlled in this observation.
The penetration of the tumor into the myometrium has been demonstrated to be related to prognosis, but this condition usually correlates with the degree of differentiation of the tumor. The correlation between steroid receptor levels and/or status and depth of invasion into the myometrium by tumor does not show a consistent trend, especially if the study controls for tumor differentiation. Chambers et al. [23] showed that, in patients with early endometrial cancer, there was a statistically significant association (p = 0.025) between estrogen receptor status and depth of myometrial invasion; in fact, in stage I and II patients, 68.4 percent of patients with no myometrial invasion had estrogen receptor-rich tumors, whereas only 44.0 percent of the patients with tumors invading at least 50 percent of the myometrium had estrogen-rich tumors. On further analysis, however, the covariable grade appears to account for this observation. Analysis of the estrogen receptor level and depth of invasion showed no correlation. There was no correlation between progestin receptor status and myometrial invasion. The mean progestin receptor level for tumor invading less than 50 percent was, however, 180.4 fmol/mg of protein compared with 92.1 fmol/mg of protein for tumors invading at least 50 percent. Although these values were significantly different, both levels represent high content of progestin receptor. Creasman et al. [25] also showed no relationship between the invasiveness of the tumor into the myometrium and the hormonal receptor status. Quinn et al. [28] , in a study of 155 endometrial carcinomas, carefully analyzed the steroid receptor level and/or status of the tumors and myometrial invasion, controlling not only for degree of differentiation but also for histologic subtype. They showed that deep invasion (greater than two-thirds through the myometrium) was significantly less likely in the estrogen receptor-positive tumor (p < 0.001) or the progestin receptor-positive tumor (p < 0.001) (both .5 fmol/mg of protein). This relationship held true, however, only for poorly differentiated estrogen receptor-rich tumors if histologic subtypes were analyzed separately. Furthermore, no poorly differentiated, deeply invasive tumor was estrogen receptor-rich, and the mean estrogen receptor level (p = 0.01) and mean progestin receptor level (p < 0.05) were significantly lower in well-differentiated tumors invading more than one-third of the myometrium than those invading less. Others have not controlled for the grade of the tumor in investigating the depth of invasion [27, 29] .
Geisinger et al. [24] , in a series of 43 patients with stages I to IV disease, showed a significant relationship between receptor status (>10 fmol/mg of protein for both receptors) and vascular space invasion, the majority of the tumors with such invasion being negative for both receptors, while, in neoplasms lacking such invasion, 81 percent were estrogen receptor-positive and 91 percent were progestin receptor-positive.
Age and steroid receptor content or status do not correlate, as is noted by several authors [23, 29] . The peritoneal cytology at hysterectomy and hormonal receptor status have no correlation [23, 25] . Others have shown no correlation between menstrual status and mean estrogen or progestin content of the tumor [26, 29] . SURVIVAL AND STEROID RECEPTORS Many studies have noted the influence of the steroid receptor content on survival. Table 1 summarizes the results from the papers discussed. Martin et al. [37] showed a significantly increased survival time for women with estrogen receptor-positive adenocarcinoma compared with negative ones (p < 0.02). Geisinger et al. [24] found that progestin-positive tumor (p = 0.003) as well as quantitative level of the progestin receptor (p = 0.012) were significantly related to survival. In dividing the progestin levels into 0-10 fmol/mg of protein, 10-200 fmol/mg of protein, and >200 fmol/mg of protein, little difference in survival (deaths from all causes) was found between the latter two groups, suggesting that simply the presence of the progestin receptor protein, and not the level of content above the cut-off of 10 fmol/mg of protein, gave a better prognosis for survival. Analyzing deaths due to cancer, the presence or absence of the estrogen receptor protein and the quantitative levels of the estrogen receptor were both significant variables for survival. Dividing estrogen receptor levels into 0, 1 to 100 fmol/mg of protein, and greater than 100 fmol/mg of protein, three distinct survival categories were generated. Patients with tumors having no estrogen receptor content had the worst prognosis; those in the middle group had an intermediate prognosis, and no patient with greater than 100 fmol/mg protein died secondary to endometrial cancer.
Creasman et al. [25] showed that estrogen receptor-positive status (p < 0.01), progestin receptor-positive status (p < 0.001), and combined estrogen receptor-and progestin receptor-positive status (p < 0.01) had a significantly better disease-free survival than those with negative receptor status tumors. Furthermore, by multiregression analysis, estrogen receptor status, progestin receptor status, and combined estrogen and progestin receptor status were each independent predictors of survival. In further analysis of this finding, progestin receptor status was more significant than estrogen receptor status in predicting survival. In addition, hormonal receptor status replaced histologic grade and nuclear grade of the tumor as an independent predictor of survival.
In 187 patients with stage I and II disease, Chambers et al. [23] showed that the patients with estrogen receptor-rich tumors (p = 0.0003) or with progestin receptorrich tumors (p = 0.0016) had a significantly increased survival compared with those having receptor-poor tumors. The receptor protein status was then divided into low, intermediate, and high ranges for the estrogen receptor content, choosing 0-19 fmol/mg of protein, 20-100 fmol/mg of protein, and greater than 100 fmol/mg of protein respectively. Three distinct survival curves were generated. Analysis of these curves demonstrated that the intermediate and high-range curves were not statistically different, but both were significantly different from the low-range curve. The patients in the latter two groups had statistically better survival than those in the low-range group. In a similar fashion, the levels of the progestin receptor content were divided into three distinct ranges: 0-6 fmol/mg of protein, 7-50 fmol/mg of protein, and greater than 50 fmol/mg of protein. Analysis showed that the survival curves for the low and intermediate ranges were not significantly different; however, both were significantly different from the curve of the high range. The patients in the last group had statistically better prognosis than those in the other two groups. Using this information in this population, it appeared that the appropriate cut-offs were [54] . Ten years later, the first series of patients treated with progestins for endometrial cancer appeared. Reviews of these early studies of the systematic use of progestins in advanced endometrial cancer report an objective response rate of approximately one-third, usually in the well-differentiated tumors [55] .
In 1981, Ehrlich et al. [6] , in an analysis of 24 patients with advanced or recurrent endometrial adenocarcinoma in which progestin receptors were measured prior to therapy, had an 80 percent objective response to progestin therapy in patients with progestin receptor-positive tumors compared with a 6 percent response in those with negative tumors (p < 0.001). Also, in this series, 94 percent of nonresponders had tumors which were progestin receptor-poor. As summarized in this paper, of the 70 patients with advanced or recurrent adenocarcinoma, 94 percent of the patients with progestin-positive tumors responded to progestin therapy, while only 11 percent of those with progestin-negative tumors responded. This difference in response rate was statistically significant (p < 0.001). Quinn et al. [39] in 1985 reported on 22 patients with recurrent or advanced disease treated with medroxyprogesterone acetate; none of the 13 patients with progestin receptor-negative tumors responded, while only two of nine (22 percent) with progestin receptor-positive tumors responded, and both were complete responses. Quinn et al. [39] analyzed 94 cases and found that 82 percent of patients responding to progestin had progestin receptor-rich tumors, while only 11 percent of those with progestin receptor-poor tumors responded to progestin. In this review it was also noted that estrogen receptor status was as good as progestin receptor status in predicting response, with 71 percent of the patients with estrogen receptorrich tumors responding and only 5 percent of patients with estrogen receptor-poor tumors.
Kauppila et al. [38] , in a 1980 study of 15 (20 percent) . In this series, all patients had previously been treated with medroxyprogesterone acetate, which lowers the receptor protein levels, so that this observation needs to be confirmed in patients with no prior hormonal therapy.
Tamoxifen, a non-steroidal estrogen agonist-antagonist, with predominantly antagonistic properties, has also been used in the treatment of recurrent endometrial cancer [56] [57] [58] [59] . It binds to the estrogen receptor and blocks the effect of the estrogen receptor complex. Swenerton [59] , in a 1980 study of 12 patients with advanced endometrial cancer, used tamoxifen and reported one out of ten evaluable patients showed a complete response and two partial responses. The response was a function of the grade of the tumor, with the undifferentiated tumors unlikely to respond. Schwartz et al. [57] showed that tamoxifen can induce the progestin receptor in endometrial cancer, thus suggesting the use of the combination of tamoxifen with progestins; however, Carlson et al. [58] , using this combination, showed only a 33 percent total response rate, which is not superior to the usual response to progestin therapy alone. Danazol, a derivative of ethinyl testosterone, has been reported to have progestin-like effects in endometrial adenocarcinoma [60] , thus suggesting another agent which may be effective in treatment.
SUMMARY
The identification of sex steroid receptor proteins in endometrial cancer has led to a rational basis for many observations concerning the response of advanced and recurrent tumors to hormonal therapy. There are, however, several problems with the usual biochemical assays of the receptor protein content of the tumor. First, there are technical considerations, e.g., the time between obtaining the specimen and assaying it; second, obtaining the tissue leads to contamination with non-malignant components. Newer immunohistochemical methods with monoclonal antibodies for localization and quantification of the sex steroid receptors may enable better correlation with the biologic behavior by correcting for the non-malignant fragments. These methods will need further development and acceptance. The level of estrogen and progestin receptor protein in the tumor inversely parallels the grade of the tumor; that is, the higher the level of sex steroid content, the greater the differentiation of the tumor. The concept of sex steroid receptor-rich tumors leads to arbitrarily chosen cut-off levels; these may affect which clinicopathologic features are significantly associated with the hormone receptor status. In analyzing survival, for example, the presence of high levels of the sex steroid receptor protein, in general, predicts a favorable survival. Increasing the level of sex steroid receptor content may also identify groups of patients whose survival is markedly superior to the patients with lower levels. In multiregression analysis, the receptor status of the tumor may become an independent predictor of survival, replacing even histologic grade. By changing the cut-off levels chosen, however, the receptor protein status may also change; it may, in fact, be that the presence of any receptor protein in the tumor is sufficient to identify a good risk factor. On the other hand, the group of patients whose tumors lack any receptor protein do poorly, and this group may respond better to cytotoxic chemotherpy than to hormonal therapy. Thus, the exact role of the sex steroid receptor protein in endometrial cancer as a predictor for treatment or for survival will demand further investigations controlling for the factors discussed and using of new immunohistochemical techniques as well as of biochemical assays.
